Back

State of the art in platelet P2Y12 iinhibition in acute coronary syndromes

30 August 2016 (16:30 - 16:48)
Organised by:
Congress Presentation Part of: Rapid platelet P2Y12 iinhibition in acute coronary syndromes Thrombosis and platelets ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Jean-Philippe Collet

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail
Greater efficacy of prasugrel and ticagrelor administered at first medical contact compared to a switching strategy during the first hours after primary percutaneous coronary intervention
Doctor A. Marcano Fernandez (L'hospitalet De Llobregat, ES)
Abstract Slides Video
Presentation thumbnail
Chewing versus traditional swallowing of ticagrelor to accelerate platelet inhibition in acute coronary syndrome- the CHEERS study
Doctor E. Asher (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Doctor A. Eisen (Petah Tikva, IL)
Abstract Slides Video
Presentation thumbnail
Future direction for research in platelet P2Y12 iinhibition in acute coronary syndromes
Professor K. Huber (Vienna, AT)
Slides Video

Access the full session

Session thumbnail
Rapid platelet P2Y12 iinhibition in acute coronary syndromes

The Event

Event poster

ESC Congress 2016

30 August 2016 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy
31 August 2019
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Presentation
Injectable and intravenous P2Y12 inhibitors in patients with acute myocardial infarction.
26 August 2022
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources